Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies

• Main Authors: Naor Bar-Zeev, PhD (Author), Todd D Swarthout, MSc (Author), Dean B Everett, ProfPhD (Author), Maaike Alaerts, PhD (Author), Jacquline Msefula, BSc (Author), Comfort Brown, Dipl (Author), Sithembile Bilima, BSc (Author), Jane Mallewa, MD (Author), Carina King, PhD (Author), Anne von Gottberg, ProfPhD (Author), Jennifer R Verani, MD (Author), Cynthia G Whitney, MD (Author), Charles Mwansambo, FRCPCH (Author), Stephen B Gordon, ProfPhD (Author), Nigel A Cunliffe, ProfPhD (Author), Neil French, ProfPhD (Author), Robert S Heyderman, ProfPhD (Author)
• Format: Book
• Published: Elsevier, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype invasive pneumococcal disease among va...